Clinical Trial Update: Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating venetoclax plus azacitidine followed by donor lymphocyte infusion for very high-risk acute myeloid leukemia in patients undergoing allo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Venetoclax (venetoclax)

Snippet

Sponsor: Antonio M Jimenez Jimenez | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: SUSPENDED